Log In
Print this Print this

biosimilar basiliximab (STI-003)

  Manage Alerts
Collapse Summary General Information
Company Mabtech Ltd.
DescriptionBiosimiliar of basiliximab, a chimeric mAb against iInterleukin-2 (IL-2) receptor alpha chain (CD25) receptor
Molecular Target Interleukin-2 (IL-2) receptor alpha chain (CD25)
Mechanism of ActionBinds interleukin-2 (IL-2) receptor alpha chain (CD25); Antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II/III
Standard IndicationOrgan transplant
Indication DetailsPrevent acute organ transplant rejection in patients undergoing kidney transplants
Regulatory Designation
PartnerSorrento Therapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today